Coegin Pharma

5,16 SEK

+5,31 %

Mindre end 1K følgere

COEGIN

Nordic SME

Biotechnology & Pharmaceuticals

Health Care

Oversigt

Finansielt overblik og estimater

Ejerskab

Investorkonsensus

+5,31 %

-15,13 %

-6,18 %

+44,13 %

+34,03 %

+33,33 %

-63,72 %

-74,27 %

-83,78 %

Coegin Pharma is a Swedish biotechnology company with dermacosmetic projects for hair growth and skin pigmentation, as well as drug candidates for the treatment of heart attacks and leukemia. What the projects have in common is that they are based on patented technology platforms and collaborations with researchers and academics internationally. Coegin Pharma has its headquarters in Lund.

Markedsværdi

128,37 mio. SEK

Aktieomsætning

85,62 t SEK

Omsætning

-

EBIT %

-

P/E

-

Udbytteafkast, %

-

Omsætning og EBIT-margin

Omsætning

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender

26.2

2026

Årsrapport '25

Alle

Selskabsmeddelelser

ViserAlle indholdstyper

Selskabsmeddelelse27.11.2025, 08.45

Coegin Pharma's Nomination Committee appointed for the 2026 Annual General Meeting

Selskabsmeddelelse20.11.2025, 13.50

Coegin Pharma AB (publ) publishes its quarterly report for the third quarter of 2025

Pressemeddelelse14.11.2025, 13.42

First Follicopeptide® powered product available for consumer pre-orders November 16 - a historic milestone for Coegin Pharma

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Pressemeddelelse6.11.2025, 13.45

Coegin introduces new tailor-made Follicopeptide complementary product - launching early 2026

Selskabsmeddelelse17.10.2025, 15.05

Coegin Pharma enters collaboration with Hårklinikken - expands Follicopeptide® commercialization with a world renowned hair clinic brand

Pressemeddelelse13.10.2025, 08.02

Coegin Pharma establishes own agile production facility in Denmark - ensuring control, scalability, and cost efficiency for next phase of growth

Selskabsmeddelelse17.9.2025, 12.30

Coegin Pharma enters collaboration with Polish distributor Mercapharm - expands Follicopeptide® commercialisation to Poland

Selskabsmeddelelse10.9.2025, 13.00

Coegin Pharma enters collaboration with Swedish retailer Gents - kicks off next phase of Follicopeptide commercialisation

Selskabsmeddelelse21.8.2025, 12.30

Coegin Pharma AB (publ) publishes its Interim Report for the second quarter of 2025

Pressemeddelelse20.8.2025, 06.30

Coegin Pharma provides status update ahead of the upcoming commercialisation of its first Follicopeptide-based hair growth product

Selskabsmeddelelse12.8.2025, 12.45

Coegin Pharma changes language for company communication to English

Pressemeddelelse2.7.2025, 06.30

Coegin Pharma has reduced product cost by 80 percent - moving closer to the launch of Follicopeptide

Selskabsmeddelelse22.5.2025, 11.30

Communiqué from the Annual General Meeting of Coegin Pharma AB (publ)

Selskabsmeddelelse22.5.2025, 06.35

Coegin Pharma AB publishes its quarterly report for the first quarter of 2025

Selskabsmeddelelse29.4.2025, 10.45

Coegin Pharma AB publishes Annual Report for the financial year 2024

Selskabsmeddelelse16.4.2025, 11.30

Notice of Annual General Meeting in Coegin Pharma AB (publ)

Pressemeddelelse6.3.2025, 13.20

Coegin Pharma announces progress in Follicopeptide launch preparations

Selskabsmeddelelse27.2.2025, 07.38

Coegin Pharma AB (publ) publishes its year-end report for 2024

Pressemeddelelse23.1.2025, 07.27

Groundbreaking cancer treatment research published in "Nature Communications"

Pressemeddelelse12.12.2024, 07.30

Coegin Pharma invites to a Q&A on the hair growth project Follicopeptide

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.